Posted by Michael Wonder on 20 Feb 2023
TGA grants provisional approval to Moderna’s COVID-19 bivalent (Spikevax Bivalent Original/Omicron BA.4-5) booster dose vaccine
20 February 2023 - On 17 February, 2023, the TGA granted provisional approval to Moderna’s bivalent COVID-19 vaccine: elasomeran and davesomeran (Spikevax Bivalent Original/Omicron BA.4-5) for use as a booster dose in individuals aged 12 years and older.
This is the second bivalent vaccine targeting the Omicron BA.4-5 sub-variants that has been provisionally approved by the TGA and follows provisional approval of Pfizer’s Comirnaty Bivalent Omicron BA.4/BA.5 COVID-19 vaccine on 20 January 2023.
